- Home
- LLYVK vs IONS Comparison
LLYVK vs IONS Comparison
Compare LLYVK & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- IONS
- Stock Information
- Founded
- LLYVK 1991
- IONS 1989
- Country
- LLYVK United States
- IONS United States
- Employees
- LLYVK N/A
- IONS N/A
- Industry
- LLYVK Broadcasting
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVK Industrials
- IONS Health Care
- Exchange
- LLYVK Nasdaq
- IONS Nasdaq
- Market Cap
- LLYVK 8.4B
- IONS 6.8B
- IPO Year
- LLYVK N/A
- IONS 1991
- Fundamental
- Price
- LLYVK $90.25
- IONS $72.39
- Analyst Decision
- LLYVK
- IONS Strong Buy
- Analyst Count
- LLYVK 0
- IONS 20
- Target Price
- LLYVK N/A
- IONS $75.35
- AVG Volume (30 Days)
- LLYVK 273.8K
- IONS 2.1M
- Earning Date
- LLYVK 01-01-0001
- IONS 11-05-2025
- Dividend Yield
- LLYVK N/A
- IONS N/A
- EPS Growth
- LLYVK N/A
- IONS N/A
- EPS
- LLYVK N/A
- IONS N/A
- Revenue
- LLYVK N/A
- IONS $944,050,000.00
- Revenue This Year
- LLYVK N/A
- IONS $24.01
- Revenue Next Year
- LLYVK $11.45
- IONS $4.06
- P/E Ratio
- LLYVK N/A
- IONS N/A
- Revenue Growth
- LLYVK N/A
- IONS 16.05
- 52 Week Low
- LLYVK $54.20
- IONS $23.95
- 52 Week High
- LLYVK $102.62
- IONS $73.92
- Technical
- Relative Strength Index (RSI)
- LLYVK 43.48
- IONS 81.80
- Support Level
- LLYVK $87.82
- IONS $69.40
- Resistance Level
- LLYVK $89.98
- IONS $71.87
- Average True Range (ATR)
- LLYVK 2.06
- IONS 1.71
- MACD
- LLYVK -0.67
- IONS -0.07
- Stochastic Oscillator
- LLYVK 33.75
- IONS 85.92
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.